ASTRAZENECA PLC DL-,25/ GB0009895292 /
02/10/2024 20:26:33 | Chg. +1.650 | Volume | Bid20:26:33 | Ask20:26:33 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
143.350EUR | +1.16% | - Turnover: - |
143.350Bid Size: - | 144.250Ask Size: - | 222.49 bill.EUR | - | - |
GlobeNewswire
12/08
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire
08/08
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire
06/08
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
26/06
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
18/06
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
13/06
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
08/05
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
06/05
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire
02/05
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...